Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Axsome Therapeutics Inc (AXSM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: AXSM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $178.1
Year Target Price $178.1
| 14 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.95% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.09B USD | Price to earnings Ratio - | 1Y Target Price 177.05 |
Price to earnings Ratio - | 1Y Target Price 177.05 | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 72.21 - 139.13 | Updated Date 06/29/2025 |
52 Weeks Range 72.21 - 139.13 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -64.39% | Operating Margin (TTM) -45.67% |
Management Effectiveness
Return on Assets (TTM) -26.17% | Return on Equity (TTM) -282.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4999392686 | Price to Sales(TTM) 11.78 |
Enterprise Value 4999392686 | Price to Sales(TTM) 11.78 | ||
Enterprise Value to Revenue 11.57 | Enterprise Value to EBITDA -14.81 | Shares Outstanding 49236400 | Shares Floating 38316232 |
Shares Outstanding 49236400 | Shares Floating 38316232 | ||
Percent Insiders 16.43 | Percent Institutions 77.28 |
Analyst Ratings
Rating 4.74 | Target Price 178.1 | Buy 5 | Strong Buy 14 |
Buy 5 | Strong Buy 14 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Axsome Therapeutics Inc
Company Overview
History and Background
Axsome Therapeutics Inc. was founded in 2012. It is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. Key milestones include the FDA approvals of Auvelity and Sunosi (acquired).
Core Business Areas
- CNS Therapeutics Development: Focuses on developing and commercializing novel therapies for CNS conditions, including depression, Alzheimer's disease agitation, and narcolepsy.
Leadership and Structure
Herriot Tabuteau, MD, is the CEO. The company has a board of directors overseeing strategic decisions. The organizational structure includes departments for research, clinical development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Auvelity: Auvelity is an oral NMDA receptor antagonist and sigma-1 receptor agonist indicated for the treatment of major depressive disorder (MDD). Competitors include SSRIs, SNRIs, and other antidepressants. Axsome is still growing its market share in this therapeutic area.
- Sunosi: Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Competitors include Wakix, Nuvigil, and Provigil. Axsome acquired Sunosi in 2022.
- AXS-05 (dextromethorphan-bupropion): This is the same active ingredient as Auvelity, however it has indications for Alzheimer's disease agitation. This drug is in Phase 3 clinical trials.
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, driven by unmet needs for effective treatments for various neurological and psychiatric disorders. This market faces significant regulatory hurdles and high R&D costs.
Positioning
Axsome is positioning itself as an innovator in CNS therapeutics, focusing on developing differentiated products with novel mechanisms of action. Its competitive advantage lies in its pipeline of innovative therapies and successful FDA approvals.
Total Addressable Market (TAM)
The TAM for depression and other CNS disorders is estimated to be in the billions of dollars. Axsome is positioned to capture a significant share of this market with its innovative therapies and targeted commercialization strategy.
Upturn SWOT Analysis
Strengths
- Innovative pipeline
- Approved therapies (Auvelity and Sunosi)
- Strong intellectual property
- Experienced management team
Weaknesses
- Limited commercial infrastructure (still expanding)
- Reliance on a few key products
- High R&D expenses
- Dependence on successful clinical trials and regulatory approvals
Opportunities
- Expansion of Auvelity and Sunosi into new markets
- Development of new CNS therapies
- Potential for strategic partnerships and acquisitions
- Addressing unmet needs in CNS disorders
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- VRTX
- TEVA
Competitive Landscape
Axsome faces competition from established pharmaceutical companies with larger commercial infrastructure and broader product portfolios. Its advantage lies in its innovative therapies and focus on unmet needs in CNS disorders.
Major Acquisitions
Sunosi (from Jazz Pharmaceuticals)
- Year: 2022
- Acquisition Price (USD millions): 50
- Strategic Rationale: The acquisition of Sunosi expanded Axsome's portfolio of CNS therapies and provided access to an established commercial infrastructure in the sleep disorder market.
Growth Trajectory and Initiatives
Historical Growth: Axsome's historical growth has been driven by successful clinical trials and regulatory approvals. The approval and launch of Auvelity marked a significant milestone.
Future Projections: Analyst estimates project continued revenue growth driven by Auvelity and Sunosi sales. Future growth depends on pipeline progress and successful commercialization efforts.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Auvelity, advancing the clinical development of AXS-05 in Alzheimer's disease agitation, and exploring new therapeutic areas.
Summary
Axsome Therapeutics is a promising biopharmaceutical company focused on CNS disorders, particularly in depression and sleep disorders. The company's approval and commercialization of Auvelity represents a major achievement. The company's weakness lies in limited commercial infrastructure and heavy dependence on Auvelity and Sunosi. Key risks include competition and the results of the AXS-05 clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Axsome Therapeutics Inc. investor relations
- SEC filings
- Analyst reports
- Company press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axsome Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-11-19 | Founder, Chairman, CEO & President Dr. Herriot Tabuteau M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 712 | Website https://www.axsome.com |
Full time employees 712 | Website https://www.axsome.com | ||
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.